GlobeNewswire - News from Washington http://www.10gbhost.com/RssFeed/stateprovince/Washington/feedTitle/GlobeNewswire%20-%20News%20from%20Washington Contains the last 20 releases newsdesk@globenewswire.com (NewsDesk) Fri, 05 Feb 2021 13:00:00 GMT webmaster@globenewswire.com (Webmaster) http://www.10gbhost.com/news-release/2021/02/05/2170659/0/en/Neoleukin-Therapeutics-to-Participate-in-Guggenheim-Healthcare-Talks-2021-Oncology-Days.html http://www.10gbhost.com/news-release/2021/02/05/2170659/0/en/Neoleukin-Therapeutics-to-Participate-in-Guggenheim-Healthcare-Talks-2021-Oncology-Days.html Nasdaq:NLTX US64049K1043 Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design?de novo?protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the Guggenheim Healthcare Talks | 2021 Oncology Days on Friday, March 12, 2021 at 3 p.m. Eastern Time.

]]>
Fri, 05 Feb 2021 13:00 GMT 2170659 en GlobeNewswire Inc. Neoleukin Therapeutics, Inc. Fri, 05 Feb 2021 13:00 GMT Calendar of Events Biotechnology
http://www.10gbhost.com/news-release/2021/02/05/2170399/0/en/Avista-Corp-Board-Increases-Common-Stock-Dividend.html http://www.10gbhost.com/news-release/2021/02/05/2170399/0/en/Avista-Corp-Board-Increases-Common-Stock-Dividend.html NYSE:AVA US05379B1070 Avista Corp. Board Increases Common Stock Dividend SPOKANE, Wash., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Avista Corp.’s (NYSE: AVA) board of directors has declared a quarterly dividend of $0.4225 per share on the company’s common stock, an increase of $0.0175 per share (4.3 percent), yielding and annualized dividend of $1.69. The common stock dividend is payable March 15, 2021, to shareholders of record at the close of business on Feb. 19, 2021.

]]>
Fri, 05 Feb 2021 00:05 GMT 2170399 en GlobeNewswire Inc. Avista Corporation Fri, 05 Feb 2021 00:05 GMT Dividend Reports and Estimates
http://www.10gbhost.com/news-release/2021/02/04/2169516/0/en/Sana-Announces-Upsized-Pricing-of-Initial-Public-Offering.html http://www.10gbhost.com/news-release/2021/02/04/2169516/0/en/Sana-Announces-Upsized-Pricing-of-Initial-Public-Offering.html Nasdaq:SANA US7995661045 Sana Announces Upsized Pricing of Initial Public Offering SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a public offering price of $25.00 per share. All of the shares of common stock are being offered by Sana. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sana, are expected to be $587.5 million. Sana’s common stock is expected to begin trading on The Nasdaq Global Select Market on February 4, 2021, under the ticker symbol “SANA.” The offering is expected to close on February 8, 2021, subject to the satisfaction of customary closing conditions. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3,525,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, and, if exercised in full, would result in aggregate gross proceeds of approximately $675.6 million.

]]>
Thu, 04 Feb 2021 04:22 GMT 2169516 en GlobeNewswire Inc. Sana Biotechnology, Inc Thu, 04 Feb 2021 04:22 GMT Company Announcement Sana Biotechnology biotechnology
http://www.10gbhost.com/news-release/2021/02/04/2169507/0/en/Miller-Mendel-files-a-patent-infringement-lawsuit-against-Washington-County-Sheriff-s-Office-for-use-of-infringing-Guardian-Alliance-Technologies-software.html http://www.10gbhost.com/news-release/2021/02/04/2169507/0/en/Miller-Mendel-files-a-patent-infringement-lawsuit-against-Washington-County-Sheriff-s-Office-for-use-of-infringing-Guardian-Alliance-Technologies-software.html Miller Mendel files a patent infringement lawsuit against Washington County Sheriff’s Office for use of infringing Guardian Alliance Technologies software SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- On February 1, 2021, attorneys for Miller Mendel filed a?second patent infringement lawsuit?related to use of the Guardian Alliance Technologies background investigation software.? The complaint in the most recent lawsuit, filed in Oregon Federal District Court, alleges Washington County Sheriff’s Office infringes on?Miller Mendel’s U.S. Patent 10,043,188 B2, through its use of the Guardian Alliance Technologies background investigation software. Miller Mendel believes based on records it has obtained that the?Washington County Sheriff’s Office?knew of Miller Mendel’s patent and proceeded forward nevertheless, which Miller Mendel contends constitutes willful infringement of Miller Mendel’s patent rights.

]]>
Thu, 04 Feb 2021 02:50 GMT 2169507 en GlobeNewswire Inc. Miller Mendel, Inc Thu, 04 Feb 2021 02:50 GMT Law & Legal Issues
http://www.10gbhost.com/news-release/2021/02/03/2169411/0/en/Costco-Wholesale-Corporation-Reports-January-Sales-Results.html http://www.10gbhost.com/news-release/2021/02/03/2169411/0/en/Costco-Wholesale-Corporation-Reports-January-Sales-Results.html Nasdaq:COST US22160K1051 Costco Wholesale Corporation Reports January Sales Results ISSAQUAH, Wash., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today reported net sales of $13.64 billion for the retail month of January, the four weeks ended January 31, 2021, an increase of 17.9 percent from $11.57 billion last year.

]]>
Wed, 03 Feb 2021 21:15 GMT 2169411 en GlobeNewswire Inc. Costco Wholesale Corporation Wed, 03 Feb 2021 21:15 GMT Company Announcement
http://www.10gbhost.com/news-release/2021/02/03/2169192/0/en/Atossa-Therapeutics-Announces-Two-Year-Update-of-FDA-Approved-Expanded-Access-Treatment-with-Endoxifen.html http://www.10gbhost.com/news-release/2021/02/03/2169192/0/en/Atossa-Therapeutics-Announces-Two-Year-Update-of-FDA-Approved-Expanded-Access-Treatment-with-Endoxifen.html Nasdaq:ATOS US04962H2094 Atossa Therapeutics Announces Two-Year Update of?FDA-Approved Expanded Access Treatment with Endoxifen SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces updated findings following 26 months of Expanded Access (or “compassionate use”) single-patient studies of Atossa’s Endoxifen.

]]>
Wed, 03 Feb 2021 14:30 GMT 2169192 en GlobeNewswire Inc. Atossa Therapeutics, Inc. Wed, 03 Feb 2021 14:30 GMT Health $ATOS #expandedaccess #Endoxifen
http://www.10gbhost.com/news-release/2021/02/03/2169151/0/en/SportsArt-Announces-Expansion-of-Its-Energy-Producing-Fitness-Equipment-Line-ECO-POWR-with-Addition-of-the-Elite-Series.html http://www.10gbhost.com/news-release/2021/02/03/2169151/0/en/SportsArt-Announces-Expansion-of-Its-Energy-Producing-Fitness-Equipment-Line-ECO-POWR-with-Addition-of-the-Elite-Series.html SportsArt Announces Expansion of Its Energy Producing Fitness Equipment Line ECO-POWR with Addition of the Elite Series The Elite ECO-POWR Series treadmill, elliptical and cycle offset electricity consumption in compact design]]> Wed, 03 Feb 2021 14:00 GMT 2169151 en GlobeNewswire Inc. Sports Art America, Inc Wed, 03 Feb 2021 14:00 GMT Product / Services Announcement SportsArt green fitness ECO-POWR Elite Series Ruben Mejia gym equipment sustainability sustainable fitness ECO-POWR Elite Series http://www.10gbhost.com/news-release/2021/02/02/2168599/0/en/Adaptive-Biotechnologies-to-Report-Fourth-Quarter-and-Full-Year-2020-Financial-Results-on-February-24-2021.html http://www.10gbhost.com/news-release/2021/02/02/2168599/0/en/Adaptive-Biotechnologies-to-Report-Fourth-Quarter-and-Full-Year-2020-Financial-Results-on-February-24-2021.html Nasdaq:ADPT US00650F1093 Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) ?a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year of 2020 after market close on Wednesday, February 24, 2021. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

]]>
Tue, 02 Feb 2021 21:05 GMT 2168599 en GlobeNewswire Inc. Adaptive Biotechnologies Tue, 02 Feb 2021 21:05 GMT Calendar of Events
http://www.10gbhost.com/news-release/2021/02/02/2168563/0/en/Immediate-Needs-to-Address-Remote-Learning-Inequity-for-Students.html http://www.10gbhost.com/news-release/2021/02/02/2168563/0/en/Immediate-Needs-to-Address-Remote-Learning-Inequity-for-Students.html Immediate Needs to Address Remote Learning Inequity for Students The Washington-based Technology Alliance releases new recommendations as part of comprehensive report]]> Tue, 02 Feb 2021 19:39 GMT 2168563 en GlobeNewswire Inc. Technology Alliance Tue, 02 Feb 2021 19:39 GMT Company Announcement http://www.10gbhost.com/news-release/2021/02/02/2168338/0/en/Atossa-Therapeutics-Phase-2-Endoxifen-Breast-Cancer-Study-Produces-Substantially-Positive-Results-Allowing-Study-to-be-Halted-Early.html http://www.10gbhost.com/news-release/2021/02/02/2168338/0/en/Atossa-Therapeutics-Phase-2-Endoxifen-Breast-Cancer-Study-Produces-Substantially-Positive-Results-Allowing-Study-to-be-Halted-Early.html Nasdaq:ATOS US04962H2094 Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announces that based on substantially positive results achieved with the patients enrolled to date in its Australian open-label Phase 2 clinical study of oral Endoxifen administered in the “window of opportunity” between diagnosis of breast cancer and surgery, Atossa has halted the study and is accelerating its Endoxifen program in the United States.

]]>
Tue, 02 Feb 2021 14:30 GMT 2168338 en GlobeNewswire Inc. Atossa Therapeutics, Inc. Tue, 02 Feb 2021 14:30 GMT Health $ATOS #Endoxifen
http://www.10gbhost.com/news-release/2021/02/02/2168329/0/en/GREATER-GOOD-CHARITIES-AND-ACTOR-CHRIS-PRATT-AWARD-NEARLY-650-000-AFTER-SUCCESSFUL-FEED-THY-NEIGHBOR-INITIATIVE-TO-COMBAT-FOOD-INSECURITY-DUE-TO-COVID-19-PANDEMIC.html http://www.10gbhost.com/news-release/2021/02/02/2168329/0/en/GREATER-GOOD-CHARITIES-AND-ACTOR-CHRIS-PRATT-AWARD-NEARLY-650-000-AFTER-SUCCESSFUL-FEED-THY-NEIGHBOR-INITIATIVE-TO-COMBAT-FOOD-INSECURITY-DUE-TO-COVID-19-PANDEMIC.html GREATER GOOD CHARITIES AND ACTOR CHRIS PRATT AWARD NEARLY $650,000 AFTER SUCCESSFUL FEED THY NEIGHBOR INITIATIVE TO COMBAT FOOD INSECURITY DUE TO COVID-19 PANDEMIC Feed Thy Neighbor is Made Possible by The Hunger Site and 12 Tomatoes]]> Tue, 02 Feb 2021 14:21 GMT 2168329 en GlobeNewswire Inc. GreaterGood.org Tue, 02 Feb 2021 14:22 GMT Arts & Entertainment Feature Article Lifestyle Other News Press releases food insecurity COVID-19 Charity Chris Pratt http://www.10gbhost.com/news-release/2021/02/02/2168167/0/en/Chinook-Receives-Rare-Pediatric-Disease-Designation-from-U-S-Food-and-Drug-Administration-for-CHK-336-for-Treatment-of-Primary-Hyperoxaluria.html http://www.10gbhost.com/news-release/2021/02/02/2168167/0/en/Chinook-Receives-Rare-Pediatric-Disease-Designation-from-U-S-Food-and-Drug-Administration-for-CHK-336-for-Treatment-of-Primary-Hyperoxaluria.html Nasdaq:KDNY US16961L1061 Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria CHK-336 On Track for Phase 1 Clinical Trial Initiation in the Second Half of 2021

]]>
Tue, 02 Feb 2021 13:15 GMT 2168167 en GlobeNewswire Inc. Chinook Therapeutics, Inc. Tue, 02 Feb 2021 13:15 GMT Health
http://www.10gbhost.com/news-release/2021/02/01/2167673/0/en/FS-Bancorp-Inc-Appoints-Pamela-M-Andrews-to-Board-of-Directors.html http://www.10gbhost.com/news-release/2021/02/01/2167673/0/en/FS-Bancorp-Inc-Appoints-Pamela-M-Andrews-to-Board-of-Directors.html Nasdaq:FSBW US30263Y1047 FS Bancorp, Inc. Appoints Pamela M. Andrews to Board of Directors MOUNTLAKE TERRACE, Wash., Feb. 01, 2021 (GLOBE NEWSWIRE) -- FS Bancorp, Inc. (NASDAQ:FSBW) (the “Company”), the holding company for 1st Security Bank of Washington (the “Bank”), today announced that Pamela M. Andrews has been appointed to the Board of Directors of the Company and the Bank.

]]>
Mon, 01 Feb 2021 21:05 GMT 2167673 en GlobeNewswire Inc. FS Bancorp, Inc. Mon, 01 Feb 2021 21:05 GMT Company Announcement Directors and Officers
http://www.10gbhost.com/news-release/2021/02/01/2167599/0/en/Award-Winning-Winemaker-Charles-Smith-Announces-New-Company-Name-HOUSE-OF-SMITH.html http://www.10gbhost.com/news-release/2021/02/01/2167599/0/en/Award-Winning-Winemaker-Charles-Smith-Announces-New-Company-Name-HOUSE-OF-SMITH.html Award-Winning Winemaker Charles Smith Announces New Company Name HOUSE OF SMITH Seattle, WA, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Charles Smith, founder of Washington’s largest winemaker-owned winery, today announced a new name for his international company – HOUSE OF SMITH. ?A prolific winemaker, Charles is the visionary and creative force behind an extensive portfolio of celebrated wines that are now fittingly housed under his name.

]]>
Mon, 01 Feb 2021 18:00 GMT 2167599 en GlobeNewswire Inc. House of Smith Mon, 01 Feb 2021 18:00 GMT Photo


]]>
GlobeNewswire Inc.
Photo


]]>
GlobeNewswire Inc.
Arts & Entertainment Food Lifestyle food beverage alcohol wine alcoholbeverage sparklingwine
http://www.10gbhost.com/news-release/2021/02/01/2167463/0/en/Corum-Client-Carenity-Acquired-by-BID-Equity.html http://www.10gbhost.com/news-release/2021/02/01/2167463/0/en/Corum-Client-Carenity-Acquired-by-BID-Equity.html Corum Client Carenity Acquired by BID Equity SEATTLE, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corum announces that their client, France-based Carenity, the developer of a social platform supporting patients and caregivers, has been acquired by German Private Equity firm BID Equity. BID Equity is merging three of its portfolio companies—XClinical, Fortress Medical Systems and Carenity—creating a new data science company delivering end-to-end coverage of the clinical development process.

]]>
Mon, 01 Feb 2021 15:00 GMT 2167463 en GlobeNewswire Inc. Corum Group Mon, 01 Feb 2021 15:00 GMT Mergers and Acquisitions health tech healthcare technology mergers and acquisitions tech M&A Corum Group software and IT companies software companies
http://www.10gbhost.com/news-release/2021/02/01/2167472/0/fr/Rachat-de-Corum-Client-Carenity-par-BID-Equity.html http://www.10gbhost.com/news-release/2021/02/01/2167472/0/fr/Rachat-de-Corum-Client-Carenity-par-BID-Equity.html Rachat de Corum Client Carenity par BID Equity SEATTLE (États-Unis), 01 févr. 2021 (GLOBE NEWSWIRE) -- Corum annonce que son client Carenity, développeur fran?ais d'une plateforme sociale soutenant les patients et soignants, a été racheté par le cabinet allemand de capital-investissement BID Equity. BID Equity fusionne trois de ses sociétés de portefeuille (XClinical, Fortress Medical Systems et Carenity), donnant ainsi naissance à une nouvelle entreprise spécialisée dans la science des données qui assurera une couverture de bout en bout du processus de développement clinique.

]]>
Mon, 01 Feb 2021 15:00 GMT 2167472 fr GlobeNewswire Inc. Corum Group Mon, 01 Feb 2021 15:00 GMT Mergers and Acquisitions
http://www.10gbhost.com/news-release/2021/02/01/2167389/0/en/2nd-Watch-Taps-Global-Technology-Services-Leader-to-Lead-Sales-Organization.html http://www.10gbhost.com/news-release/2021/02/01/2167389/0/en/2nd-Watch-Taps-Global-Technology-Services-Leader-to-Lead-Sales-Organization.html 2nd Watch Taps Global Technology Services Leader to Lead Sales Organization Cloud technology & digital services expert Chris Whaley tasked with expanding 2nd Watch’s sales leadership]]> Mon, 01 Feb 2021 14:00 GMT 2167389 en GlobeNewswire Inc. 2nd Watch Mon, 01 Feb 2021 14:01 GMT Directors and Officers http://www.10gbhost.com/news-release/2021/02/01/2167403/0/en/Change-the-Way-You-Celebrate-Valentine-s-Day-with-Papa-Murphy-s-HeartBaker-Pizza.html http://www.10gbhost.com/news-release/2021/02/01/2167403/0/en/Change-the-Way-You-Celebrate-Valentine-s-Day-with-Papa-Murphy-s-HeartBaker-Pizza.html Change the Way You Celebrate Valentine’s Day with Papa Murphy’s HeartBaker? Pizza Enjoy a Sweetheart of a Deal that includes both the beloved HeartBaker? Pizza and Chocolate Chip Cookie Dough, for a limited time]]> Mon, 01 Feb 2021 14:00 GMT 2167403 en GlobeNewswire Inc. Papa Murphy's Holdings, Inc. Mon, 01 Feb 2021 14:02 GMT HeartBaker? Pizza


]]>
GlobeNewswire Inc.
Company Announcement Papa Murphy's Papa Murphy's Pizza Fresh Pizza Pizza Take and Bake Take 'N' Bake Valentine's Deals HeartBaker Pizza Heart Pizza
http://www.10gbhost.com/news-release/2021/01/29/2166842/0/en/Chiral-Pharma-Corp-to-Assist-Philippine-Physicians-Apply-for-Compassionate-Special-Permit-CSP-to-Access-CytoDyn-s-Leronlimab-for-COVID-19-Patients-as-Philippines-FDA-Reviews-Each-A.html http://www.10gbhost.com/news-release/2021/01/29/2166842/0/en/Chiral-Pharma-Corp-to-Assist-Philippine-Physicians-Apply-for-Compassionate-Special-Permit-CSP-to-Access-CytoDyn-s-Leronlimab-for-COVID-19-Patients-as-Philippines-FDA-Reviews-Each-A.html Other OTC:CYDY US23283M1018 Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use CytoDyn will dedicate at least 200,000 vials (100,000 doses) of leronlimab from its inventory to Chiral Pharma Corp. for potential sales in the Philippines

]]>
Fri, 29 Jan 2021 21:01 GMT 2166842 en GlobeNewswire Inc. CytoDyn Inc. Fri, 29 Jan 2021 21:02 GMT Health Product / Services Announcement COVID-19 Coronavirus BIOTECHNOLOGY
http://www.10gbhost.com/news-release/2021/01/29/2166824/0/en/Corum-Client-Leading2Lean-Manufacturing-Software-Platform-Provider-Secures-Growth-Investment-from-M33-Growth.html http://www.10gbhost.com/news-release/2021/01/29/2166824/0/en/Corum-Client-Leading2Lean-Manufacturing-Software-Platform-Provider-Secures-Growth-Investment-from-M33-Growth.html Corum Client Leading2Lean, Manufacturing Software Platform Provider, Secures Growth Investment from M33 Growth SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Corum announces today that their client, Nevada-based Leading2Lean (L2L), provider of plant floor digital production and maintenance software solutions for manufacturers, has secured a growth investment from M33 Growth.

]]>
Fri, 29 Jan 2021 19:44 GMT 2166824 en GlobeNewswire Inc. Corum Group Fri, 29 Jan 2021 19:44 GMT Financing Agreements blue collar tech mergers and acquisitions tech M&A no code technology bluecollar tech software and IT companies
亚洲精品私拍国产在线播放_亚洲综合区图片小说区_亚洲日本欧美日韩高观看